Experimental drug offered to rare neurological disorder patients
NCT ID NCT06034886
Summary
This program provides access to the investigational drug troriluzole for people with spinocerebellar ataxia (SCA), a rare genetic disorder that affects movement and coordination. The program is designed for patients who have a confirmed SCA diagnosis and may include both new patients and those who previously participated in troriluzole studies. The goal is to help control disease progression while the drug continues through clinical development.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SPINOCEREBELLAR ATAXIAS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.